A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
A new prescription discount card, SmartRx, a division of Smarty, joins GoodRx and SingleCare in the prescription discount card arena. SmartRx offers its users a free discount card and a paid membership program. The SmartRx Discount Card helps consumers save up to 80% on their prescription drugs. SmartRx+ is a monthly membership program that offers rebates for doctor or dentist visits, telehealth care, prescription glasses or contacts, annual vaccines, and pet medications.
“An increase in healthcare costs over the past few years coupled with this past year’s inflation rates have really affected consumer’s bottom line. SmartRx is a smart healthcare cost saving solution that goes beyond prescription drug costs to help tackle these consumer concerns about health care costs,” Vipin Porwal, chief executive officer and founder of Smarty and SmartRx, told Formulary Watch.
SmartRx works with PBMs to pass on discounts when consumers present their SmartRx coupon or discount card at the pharmacy, Porwal said.
The membership rate for SmartyRx+ is $19 per month after a seven-day trial for $3. Users get a $15 cashback bonus rebate on their first prescription purchase, plus $30 annual rebate for vaccines, $50 a month for doctor and dental visits, $125 for annual for prescription glasses and contacts, $25 a month for pet medications, and other rebates.
In addition, the SmartRx Discount Card is accepted at more than 65,000 pharmacies nationwide.
In a recent SmartRx survey, 66% of respondents agreed or strongly agreed that prescriptions are too costly. Nearly half (48%) of respondents said they would use a subscription service that offers cashback and rebates on prescriptions.
Smarty is an online shopping destination that automatically applies the best coupon on purchases from more than 6,000 U.S. retailers and 1,500 global merchants.
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More